30 closest matches · ranked by relevance
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 25 percentage of participants
Multiple Myeloma, Neoplasms
Primary: Confirmed Best Overall Response Rate (BORR) — 37.1; 50.0; 0; 7.4 percentage of participants
Ameloblastoma · BRAF Gene Mutation
Primary: Tumor Response — 0; 0; 0; 0 Participants
Multiple Myeloma, Neoplasms
Primary: Percentage of Participants With BRAF V600 Mutation Positivity in Tumor Samples by Cancer Type — 0; 3; 11; 0 percentage of participants
Cancer
Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants
Melanoma
Primary: Number of Participants With Response According to RECIST v1.1 Criteria — 2; 2; 2; 1 Participants
Solid Tumors Harboring a BRAF V600 Mutation
Primary: Number of Participants With Dose Limiting Toxicities (DLTs): Phase 1b — 0; 0; 0; 0 Participants
Recurrent Melanoma · Stage IIIB Melanoma · Stage IIIC Melanoma
Primary: Overall Response Rate in "High Affinity" Group — 0.5 Proportion of participants
Cancer
Primary: Overall Response Rate (ORR) — 27; 39; 23; 4 Participants
Neoplasms
Primary: Best Overall Response Rate in TKI-Naive Participants — 42.3 percentage of participants
BRAF Mutant Metastatic Melanoma
Primary: Phase 1 - Safety & Recommended Phase 2 Dose (RP2D) — 60 mg
Melanoma
Primary: Number of Participants With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator for Participants Who Had…
Melanoma and Metastatic Colorectal Cancer
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) During Dose Escalation Phase — 0; 1; 0; 0 Participants
Melanoma and Brain Metastases
Primary: Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator — 4; 1; 26; 23 participants…
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Change in Kinase Expression — -20.87259; -19.64376; -16.41738; -12.5401 Sum Log 2 Fold Change Kinase Expression
Melanoma
Primary: Dose Limiting Toxicity (DLT) [Phase I] — 1 Participants
Melanoma
Primary: Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review…
Adult Solid Neoplasm
Primary: Objective Response Rate in Patients With Cancers Other Than Melanoma — 0 percentage of participants
Melanoma
Primary: Overall Survival (OS) — 26.0; 17.8 Months
BRAF or NRAS Mutant Metastatic Melanoma
Primary: Percentage of Participants With Objective Response (OR) — 4.9; 14.5; 12.0 percentage of participants
BRAF V600E Unresectable or Metastatic Melanoma · BRAF V600E Metastatic NSCLC · Melanoma
Primary: Dose Limiting Toxicities (DLTs) Experienced During Cycle 1 — 0 participants
Malignant Melanoma · Colorectal Carcinoma
Primary: Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 on Day 1 - Dose Escalation: Original Formulation — 2.02; 3.28; 4.47; 4.23 ug*hr/mL
Melanoma
Primary: Part 1: Progression Free Survival (PFS) by BIRC in Combo 450 Group as Compared to Vemurafenib Group — 14.9; 7.3 Months
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Best Overall Response Rate (BORR) — 2; 17; 1 Participants
Solid Tumor and Hematologic Malignancies
Primary: Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 23.1 Percentage of participants
Metastatic Melanoma · Brain Metastases
Primary: Intracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset — 34; 13; 1; 20 Participants
BRAF V600E Mutation Positive · Metastatic Colorectal Cancer
Primary: Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients — 17; 6; 10; 1 Participants
Melanoma and Brain Metastases
Primary: Intracranial Response (IR) Rate in Cohort A — 45 Number of participants — p=<.0001
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) — 74.6; 46.2 Percentage of Participants
Melanoma
Primary: Activity of Vemurafenib in Untreated Brain Metastases